Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory securities lawsuit

ARS Pharmaceuticals neffy coverage securities class action

Analysis based on 174 articles · First reported Aug 06, 2026 · Last updated Sep 22, 2026

Sentiment
-8
Attention
2
Articles
174
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The lawsuits add legal and reputational pressure on ARS Pharmaceuticals after the June 2026 collapse in its share price tied to the delayed CVS Health coverage decision for neffy, keeping downside risk elevated for SPRY holders. Broader market impact is limited, as the matter is company-specific and confined to the specialty pharma and shareholder litigation space.

pharmaceuticals legal services health insurance

Multiple investor-rights law firms have filed securities class action lawsuits against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) and certain of its officers, alleging violations of federal securities laws during the class period of March 9, 2026 to June 24, 2026. The complaints allege that ARS made materially false and misleading statements and concealed material adverse facts regarding the expected timeline for expanded insurance coverage for neffy, its epinephrine nasal spray, through CVS Health. According to the complaints, ARS expressed confidence that coverage would begin on July 1, 2026 and be in place for the summer and back-to-school allergy seasons. On June 24, 2026, ARS reportedly announced that it did not receive expanded insurance coverage for neffy through CVS Health by the guided July 1, 2026 deadline, and that CVS Health reserved its decision until January 2027. On this news, ARS stock reportedly fell $2.52 per share, or 23.91%, to close at $8.02 per share on June 25, 2026. Law firms including Bronstein, Gewirtz & Grossman, LLC, Pomerantz LLP, Rosen Law Firm, and Schall Brown & Schwartz LLP have issued notices urging investors to seek lead plaintiff appointment before the October 5, 2026 deadline. No class has been certified.

100 Faruqi & Faruqi filed securities class action ARS Pharmaceuticals
100 Levi & Korsinsky filed securities class action ARS Pharmaceuticals
95 Rosen Law Firm filed class action ARS Pharmaceuticals
95 Rosen Law Firm filed class action ARS Pharmaceuticals
95 Rosen Law Firm filed class action ARS Pharmaceuticals
91 ARS Pharmaceuticals disclosed zero additions
90 CVS Health reserved coverage decision ARS Pharmaceuticals
90 Pomerantz LLP filed class action lawsuit ARS Pharmaceuticals
90 Rosen Law Firm filed class action ARS Pharmaceuticals
+ 21 more actions View on Dashboard
priv
ARS Pharmaceuticals is the defendant in the securities class actions and the central subject of the event. The litigation and the underlying neffy coverage setback weigh on its stock, financing options, and reputation.
Importance 100.0 Sentiment -55.0
stock
CVS Health's decision to reserve expanded coverage of neffy until January 2027 triggered the stock drop that underpins the lawsuits. It faces no direct legal exposure in this matter.
Importance 45.0 Sentiment -10.0
priv
Bronstein, Gewirtz & Grossman, LLC is one of the lead plaintiffs firms filing and publicizing the class action against ARS Pharmaceuticals, seeking lead plaintiff appointments before October 5, 2026.
Importance 40.0 Sentiment 5.0
priv
Rosen Law Firm is among the firms pursuing the class action against ARS Pharmaceuticals and reminding investors of the October 5, 2026 lead plaintiff deadline.
Importance 35.0 Sentiment 5.0
priv
Pomerantz LLP filed and is publicizing a parallel securities class action against ARS Pharmaceuticals over the neffy coverage timeline disclosures.
Importance 35.0 Sentiment 5.0
priv
Schall Brown & Schwartz LLP filed and is soliciting lead plaintiff appointments in the class action against ARS Pharmaceuticals.
Importance 30.0 Sentiment 5.0
priv
Faruqi & Faruqi is mentioned in headlines as one of the firms alerting investors about the class action, but it is not detailed in the provided articles.
Importance 20.0 Sentiment 0.0
priv
Kaplan Fox & Kilsheimer is mentioned in headlines as one of the firms alerting investors about the class action, but it is not detailed in the provided articles.
Importance 20.0 Sentiment 0.0
priv
Levi & Korsinsky is mentioned in headlines as one of the firms alerting investors about the class action, but it is not detailed in the provided articles.
Importance 20.0 Sentiment 0.0
per
Philip Kim is an attorney at Rosen Law Firm, listed as a contact for the class action against ARS Pharmaceuticals.
Importance 20.0 Sentiment 0.0
per
Lawrence Rosen is a founding partner of Rosen Law Firm, listed as a contact for the class action against ARS Pharmaceuticals.
Importance 20.0 Sentiment 0.0
per
Peretz Bronstein is the Founding Partner of Bronstein, Gewirtz & Grossman, LLC, quoted in the firm's press releases regarding the class action against ARS Pharmaceuticals.
Importance 20.0 Sentiment 0.0
per
Brian Schall is a founding partner of Schall Brown & Schwartz LLP, listed as a contact for the class action against ARS Pharmaceuticals.
Importance 20.0 Sentiment 0.0
per
David Schwartz is a founding partner of Schall Brown & Schwartz LLP, listed as a contact for the class action against ARS Pharmaceuticals.
Importance 20.0 Sentiment 0.0
per
Danielle Peyton is a contact at Pomerantz LLP for investors regarding the class action against ARS Pharmaceuticals.
Importance 20.0 Sentiment 0.0
+ 5 more entities View on Dashboard
Bronstein, Gewirtz & Grossman, LLC co-counsel ↔ Rosen Law Firm Bronstein, Gewirtz & Grossman, LLC frequently collaborates with Rosen Law Firm as co-counsel on investor-rights class ac
Bronstein, Gewirtz & Grossman, LLC co-plaintiffs ↔ Pomerantz LLP Bronstein, Gewirtz & Grossman, LLC frequently acts as co-plaintiff with Pomerantz LLP in numerous securities class actio
Bronstein, Gewirtz & Grossman, LLC co-plaintiffs ↔ Schall Brown & Schwartz LLP Bronstein, Gewirtz & Grossman, LLC and Schall Brown & Schwartz LLP frequently act as co-plaintiffs or pursue parallel le
Bronstein, Gewirtz & Grossman, LLC co-counsel ↔ Faruqi & Faruqi Bronstein, Gewirtz & Grossman, LLC frequently acts as co-counsel with Faruqi & Faruqi LLP in numerous securities class a
Bronstein, Gewirtz & Grossman, LLC co-plaintiffs ↔ Kaplan Fox & Kilsheimer Bronstein, Gewirtz & Grossman, LLC frequently acts as a co-plaintiff with Kaplan Fox & Kilsheimer in various securities
Rosen Law Firm co-plaintiff ↔ Pomerantz LLP Rosen Law Firm frequently acts as a co-plaintiff with Pomerantz LLP in numerous investor-rights class action lawsuits ag
Rosen Law Firm co-plaintiff ↔ Schall Brown & Schwartz LLP Rosen Law Firm frequently collaborates with Schall Brown & Schwartz LLP as co-counsel or co-plaintiff in securities clas
Rosen Law Firm competitor ↔ Faruqi & Faruqi Rosen Law Firm is a global investor rights law firm that directly competes with Faruqi & Faruqi for lead plaintiff appoi
Rosen Law Firm co-plaintiffs ↔ Kaplan Fox & Kilsheimer Rosen Law Firm frequently acts as co-plaintiff with Kaplan Fox & Kilsheimer in numerous securities class action lawsuits
Pomerantz LLP co-counsel ↔ Schall Brown & Schwartz LLP Pomerantz LLP frequently acts as co-counsel with Schall Brown & Schwartz LLP in various securities class action lawsuits
+ 14 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.